Search results for "Ankylosing"
showing 10 items of 81 documents
Molecular evidence of HLA-B27 in a historical case of ankylosing spondylitis
2005
No deterioration in health-related quality of life in patients with axial spondyloarthritis followed for 5 years in ordinary outpatient clinics in th…
2019
Abstract Background Axial spondyloarthritis (ax-SpA) causes pain, fatigue, stiffness, loss of physical function and impaired health-related quality of life (HRQOL). Aims The study aimed to explore the changes in HRQOL over 5 years in patients with ax-SpA and to identify baseline predictors associated with changes in HRQOL assessed using three HRQOL measures. Methods Demographic, disease, medication and HRQOL data were collected at baseline and at 5-year follow-up. HRQOL was assessed using SF-6D, 15D and SF-36. Analyses involved McNemar, independent paired t tests and multiple regression. Results In the 240 (women 31%, men 69%) ax-SpA patients assessed (mean age 46 years), measures reflectin…
Reply to: Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: A commentary
2021
No abstract available
THU0469-HPR Sexual perception and sexual problems in patients with ankylosing spondylitis
2013
Background Ankylosing spondylitis (AS) is a chronic, systemic inflammatory rheumatic disease affecting the axial skeleton, but may also affect peripheral joints, tendons and internal organs. This disease which begins in the second or third decade may give rise to significant loss of function and impaired quality of life. Despite the known importance of sexuality as part of quality of life (1), only a few studies have explored this important issue in AS patients. Objectives To explore sexuality in patients with AS in regard to how satisfied they are with their sexual life and whether the patients think their sexuality is influenced by the disease. Methods This is a prospective, longitudinal,…
Aceclofenac versus naproxen in the treatment of ankylosing spondylitis: A double-blind, controlled study
1994
Abstract The efficacy and tolerability of aceclofenac and naproxen sodium in the treatment of ankylosing spondylitis (AS) were evaluated and compared in this double-blind, multicenter, controlled study. Of the 130 patients who entered the study, 126 patients met the inclusion criteria. Efficacy was evaluated at baseline, 15 days, and 1, 2, and 3 months using a visual analog scale for spontaneous pain, a zero to three-point scale for pain on movement and pain at rest, and measurements of chest expansion, hand-to-floor distance, Schober's test, and normal daily activities. No significant between-group differences were seen for any of the variables at baseline, except hand-to-floor distance. B…
Minimally Invasive Sacroiliac Joint Arthrodesis: Experience in a Prospective Series with 24 Patients
2014
Background: Sacroiliac (SI) joint pain conservative treatments show poor outcomes. Hypothesis: surgical treatment will show better results. Patients and methods: Prospective series: 24 patients undergoing SI fusion after failure of medical treatment and showing temporary relief with SI infiltration. Period: Nov 2009-July 2013. Gender: 9/15. 11 cases bilaterally (all ). Age: 32-71 years (mean 47.4 years). Height: 161-178 cm (mean 168.2 cm). Weight: 56-84 kg (mean 68.4 kg). Etiology: 12 degenerative/spontaneous, 7 fall on buttocks, 3 coincident with lumbar disc and 2 with lumbar posterolateral fusion. Exclusion criteria: ankylosing spondylitis, osteitis condensans ilii, sacro-iliac joint arth…
Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis
2019
not available
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?
2021
Ankylosing spondylitis (AS) is a chronic inflammatory disease with hallmarks of both autoimmune and autoinflammatory pathology. In this Review, the authors examine the evidence for both disease processes and aim to reconcile the two.Ankylosing spondylitis (AS) is a chronic inflammatory disorder of unknown aetiology. Unlike other systemic autoimmune diseases, in AS, the innate immune system has a dominant role characterized by aberrant activity of innate and innate-like immune cells, including gamma delta T cells, group 3 innate lymphoid cells, neutrophils, mucosal-associated invariant T cells and mast cells, at sites predisposed to the disease. The intestine is involved in disease manifesta…
RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?
2019
Susceptibility to ankylosing spondylitis (AS) is polygenic with more than 100 genes identified to date. These include HLA-B27 and the aminopeptidases (ERAP1, ERAP2, and LNPEPS), which are involved in antigen processing and presentation to T-cells, and several genes (IL23R, IL6R, STAT3, JAK2, IL1R1/2, IL12B, and IL7R) involved in IL23 driven pathways of inflammation. AS is also strongly associated with polymorphisms in two transcription factors, RUNX3 and T-bet (encoded by TBX21), which are important in T-cell development and function. The influence of these genes on the pathogenesis of AS and their potential for identifying drug targets is discussed here.
A2.2 Uveitis is not associated with cardiovascular disease risk factors in patients with ankylosing spondylitis
2014
Background and Objectives Ankylosing spondylitis (AS) is a chronic, autoimmune, systemic, inflammatory disease. Recently, a link has been established between autoimmune inflammatory diseases, incl. AS, and the risk of developing cardiovascular disease (CVD). Uveitis is the most frequent extraarticular location of AS - it occurs in about 25 - 40% of patients. The impact of evidence of uveitis during the course of AS still remains a challenge. Does AS with uveitis differ from AS without uveitis? The objective of this study was to detect the link between uveitis during the course of AS and the CVD risk factors in patients with AS. Materials and Methods 77 AS patients classified using the modif…